| lamivudine / Generic mfg. |
NCT00042393: An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options |
|
|
| Approved for marketing | 3b | | US | Adefovir Dipivoxil | Gilead Sciences | Chronic Hepatitis B | | | | |
NCT00023153: Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection |
|
|
| Completed | 3 | 100 | US | Adefovir Dipivoxil | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections, Chronic Hepatitis B | | 10/04 | | |
NCT00035633: A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen |
|
|
| Completed | 3 | | US | Entecavir | Bristol-Myers Squibb | Chronic Hepatitis B | 02/05 | 02/05 | | |
NCT00035789: A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen |
|
|
| Completed | 3 | | US | Entecavir | Bristol-Myers Squibb | Chronic Hepatitis B | 05/05 | 05/05 | | |
NCT00057265: A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B |
|
|
| Completed | 3 | | US, Europe, RoW | telbivudine or lamivudine | Novartis, Novartis Pharmaceuticals | Chronic Hepatitis B | 04/06 | | | |
| Completed | 3 | 173 | US | Placebo (PLB), Adefovir Dipivoxil (ADV), Lamivudine | Gilead Sciences | Chronic Hepatitis B | 05/06 | 04/10 | | |
| Completed | 3 | 240 | US, Canada, Europe, RoW | Lamivudine, Telbivudine | Novartis, Novartis Pharmaceuticals | Chronic Hepatitis B | 12/06 | 12/06 | | |
NCT00131742: Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B |
|
|
| Completed | 3 | | RoW | telbivudine, lamivudine | Novartis, Novartis Pharmaceuticals | Chronic Hepatitis B | 01/07 | 01/07 | | |
NCT00275652: A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis. |
|
|
| Completed | 3 | 6 | US | LdT (Telbivudine) and lamivudine | Mayo Clinic, Merck Sharp & Dohme LLC | Hepatitis B, Cirrhosis | 08/07 | 08/07 | | |
| Completed | 3 | 105 | Japan | LAM group, Lamivudine, ADV group, adefovir dipivoxil | GlaxoSmithKline | Chronic Hepatitis B | 01/08 | 01/08 | | |
NCT00376259: Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone |
|
|
| Terminated | 3 | 43 | US, RoW | telbivudine, adefovir dipivoxil | Novartis | Hepatitis B | 08/08 | | | |
NCT00140725: Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV) |
|
|
| Completed | 3 | 160 | RoW | Lamivudine plus Polyethylene glyco-interferon alfa-2b, Lamivudine | GlaxoSmithKline | Chronic Hepatitis B | | | | |
NCT00605384: A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection |
|
|
| Terminated | 3 | 4 | US, Europe, RoW | Entecavir + Tenofovir, Baraclude, Adefovir + continuing Lamivudine | Bristol-Myers Squibb | Chronic Hepatitis B | 02/09 | 02/09 | | |
NCT00076336: Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis |
|
|
| Completed | 3 | 232 | US, Canada, Europe, RoW | Telbivudine, LDT600, Lamivudine, Placebo | Novartis Pharmaceuticals | Hepatitis, Hepatitis B, Chronic, Cirrhosis | 12/09 | | | |
NCT01095835 / 2004-002985-39: A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV) |
|
|
| Completed | 3 | 131 | Europe | Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg, Pegasys®, Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg, Lamivudine (LAM) | Hoffmann-La Roche | Hepatitis B, Chronic | 01/10 | 01/10 | | |
DEFINE, NCT00410202: Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus |
|
|
| Completed | 3 | 629 | US, Canada, Europe, RoW | Entecavir, Baraclude, BMS-200475, Tenofovir, Viread, Adefovir, Hepsera, Lamivudine, Epivir | Bristol-Myers Squibb | Hepatitis B, Chronic | 01/11 | 07/12 | | |
NCT00362635: Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection |
|
|
| Completed | 3 | 92 | RoW | Clevudine | Bukwang Pharmaceutical | Hepatitis B | 12/11 | | | |
NCT00455091: A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma |
|
|
| Terminated | 3 | 117 | RoW | Adefovir Dipivoxil and Lamivudine, Hepsera,Zeffix | National Health Research Institutes, Taiwan, National Taiwan University Hospital, Chang Gung Memorial Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Taichung Veterans General Hospital, Changhua Christian Hospital, National Cheng-Kung University Hospital, Kaohsiung Veterans General Hospital., Kaohsiung Medical University | Hepatocellular Carcinoma | 04/12 | 04/18 | | |
NCT01580202: Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine |
|
|
| Completed | 3 | 180 | RoW | Entecavir, Lamivudine | Seoul National University Hospital | Malignancy, Hepatitis B | 06/17 | 06/17 | | |
NCT00051038: Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients |
|
|
| Completed | 2/3 | | US | Entecavir | Bristol-Myers Squibb | Hepatitis B | 10/05 | 10/05 | | |
